上述质押股份不负担重大资产重组等业绩补偿义务，对公司的生产经营、公 司治理不会产生重大影响，实际控制人亦将积极防范风险。 股东 名称 是否为控股 股东或第一 大股东及其 一致行动人 本次质押 数量（股） 占其所 持股份 比例 占公 司总 股本 比例 是否 为限 售股 是否 为补 充质 押 质押起 始日 质押到 期日 质权人 质押用 途 楼小 强 实际控制人 之一 3,450,000 5.70% 0.19% 是 否 2025年9 月 29 日 2026 年 9 月 24 日 华泰证 券股份 有限公 司 置换存 量金融 机构融 资 1、本次股份质押基本情况 证券代码：300759 证券简称：康龙化成 公告编号：2025-054 康龙化成（北京）新药技术股份有限公司 关于公司实际控制人股份质押和解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、股东股份质押及解除质押的基本情况 康龙化成（北京）新药技术股份有限公司（以下简称"公司"）近日接到公 司实际控制人之一楼小强先生的函告，获悉楼小强先生将其所持有的公司部分股 份进行了质押和解除质押，具体情况如 ...

Core Points - The Bioeconomy Index (970038) closed at 2386.01 points, up 0.61%, with a trading volume of 28.528 billion yuan and a turnover rate of 1.76% [1] - Among the index constituents, 32 stocks rose while 18 fell, with Deep Technology leading the gainers at 10.01% and Xinlitai leading the decliners at 3.96% [1] Index Constituents Summary - Major constituents of the Bioeconomy Index include: - Mindray Medical (13.81% weight) at 248.24 yuan, up 1.04% [1] - Changchun High-tech (5.41% weight) at 129.25 yuan, down 0.58% [1] - Kanglong Chemical (4.66% weight) at 35.30 yuan, down 1.26% [1] - Deep Technology (4.08% weight) at 30.66 yuan, up 10.01% [1] Capital Flow Analysis - The Bioeconomy Index constituents experienced a net outflow of 224 million yuan from main funds, while retail investors saw a net inflow of 207 million yuan [3] - Notable capital flows include: - Deep Technology with a main fund net inflow of 28.4 million yuan [3] - Mindray Medical with a main fund net inflow of 80.8494 million yuan [3] - Other companies like Boteng Co. and Zhifei Biological also showed varying net inflows and outflows [3]

Investment Rating - The industry rating is "Positive" (maintained) [7] Core Views - The report highlights that the domestic innovative drug sector is entering a phase of "engineer dividend" realization, with improved profitability and valuation breakthroughs expected [1] - The CXO sector is showing signs of recovery, with a positive outlook on CDMO commercialization orders and clinical CRO investment opportunities [2] - The upstream research sector is anticipated to benefit from a downward interest rate cycle and a recovery in global new drug development demand, with recommended stocks including Haoyuan Pharmaceutical and Bid Pharma [3] - The medical device sector is expected to experience a recovery cycle, particularly for high-value consumables and medical equipment companies, with recommendations for companies like Aikang Medical and Mindray Medical [4] - The traditional Chinese medicine sector is projected to see an earnings inflection point, with a favorable outlook for the second half of 2025 [5] - The report favors leading pharmacy chains with superior management capabilities, recommending companies such as Dazhonglin and Yifeng Pharmacy [6] - The pharmaceutical distribution sector is expected to improve, with a focus on low-positioned value and innovative business opportunities [7] Summary by Sections Innovative Drugs - Positive outlook on profitability improvement and valuation breakthroughs due to recognition by multinational corporations [1] CXO - Recovery in the sector with ongoing commercialization of small and large molecule CDMO orders [2] Upstream Research - Anticipated performance elasticity and new business expansion opportunities [3] Medical Devices - Significant growth potential in high-value consumables and medical equipment sectors [4] Traditional Chinese Medicine - Expected earnings growth and increased market interest due to improved fundamentals [5] Pharmacies - Favorable view on pharmacy chains with strong management and adaptability [6] Pharmaceutical Distribution - Positive trends in the sector with potential for operational improvements and value re-evaluation [7]

Overview - The global CRO market is projected to reach $90.03 billion by 2024, with the preclinical CRO market accounting for $27.46 billion, representing 30.5% of the total CRO market [1][9]. - The increasing prevalence of chronic diseases and heightened health awareness are driving demand for high-quality biopharmaceutical products and related research services [1][9]. Industry Barriers - The preclinical CRO sector faces significant entry barriers due to the need for experienced professionals and established operational expertise, which new entrants may struggle to acquire quickly [5][6]. - Established CROs typically have over 10 years of experience, making it challenging for newcomers to compete effectively [5]. Market Policies - The pharmaceutical manufacturing industry is a key focus for development in China, supported by various policies aimed at encouraging new drug research and optimizing approval processes [7]. - Recent policies include guidelines for improving drug quality and promoting digital healthcare, creating a favorable environment for the preclinical CRO industry [7]. Industry Chain - The upstream of the preclinical CRO industry includes suppliers of experimental materials, laboratory animals, scientific instruments, and data analysis software [8]. - The primary clients for preclinical CROs are pharmaceutical companies, which outsource research to reduce costs and improve efficiency [8]. Development Status - China's CRO market is expected to reach 89.22 billion yuan in 2024, with a year-on-year growth of 5.19%, and the preclinical CRO market is projected to reach 42.91 billion yuan, growing by 5.74% [9]. - The demand for CRO services is expanding due to the aging population and rising chronic disease rates in China [9]. Competitive Landscape - The global preclinical CRO market is dominated by established companies in the US and Western Europe, with the US holding a significant market share [10][11]. - Domestic companies like WuXi AppTec and Kanglong Chemical are gaining competitive advantages by understanding local regulations and market needs, offering tailored services at lower costs [11]. Representative Domestic Companies - WuXi AppTec reported a total revenue of 39.24 billion yuan in 2024, with a gross profit of 16.02 billion yuan and a gross margin of 40.8% [12]. - YinuoSi achieved a total revenue of 1.142 billion yuan in 2024, with 95.4% of this revenue coming from its non-clinical CRO services [12][13]. Development Trends - Future advancements in AI and big data analytics are expected to enhance drug discovery and toxicology assessments, improving efficiency and accuracy in the preclinical CRO sector [13]. - There will be a growing emphasis on personalized solutions targeting specific diseases or patient groups, necessitating diverse disease models for drug development [13].

公司名稱: 康龍化成（北京）新藥技術股份有限公司 (於中華人民共和國註冊成立的股份有限公司） 呈交日期: 2025年10月8日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 致：香港交易及結算所有限公司 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03759 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 301,537,125 | RMB | | 1 RMB | | | 301,537,125 | | 增加 / 減少 (-) | | | 0 | | | RMB | | | 0 | | 本月底結存 | | | 301,537,125 | RMB | | 1 RMB | ...

Market Overview - The Hang Seng Index rose by 0.87%, closing at 26,855 points, with a target of reaching 27,000 points [1] - The U.S. government shutdown risk remains unresolved, with the U.S. Department of Commerce announcing that subsidiaries of companies on the "entity list" will automatically be added to a "blacklist" [1] Defense Strategy - The U.S. Defense Secretary convened military leaders to discuss a strategic shift from "deterring China" to focusing on the Western Hemisphere and the U.S. mainland [2] - The new strategy may involve reducing military presence in Europe, indicating a strategic contraction rather than direct military action [2] Investment Trends - The Abu Dhabi sovereign wealth fund, managing $330 billion in assets, signaled increased investment in Asia, particularly China, which is expected to attract around $6 billion from Middle Eastern capital in 2024 [2] - The metals sector remains strong, with companies like China Nonferrous Mining and Jiangxi Copper showing significant gains [3] Technology Sector - The release of DeepSeek's latest model V3.2-Exp has significantly improved training efficiency while reducing API input/output prices by over 50% [4] - Major tech companies are adapting to domestic chips, with stocks like Hua Hong Semiconductor and SenseTime seeing substantial increases [4] Tesla Developments - Tesla announced plans to expand its humanoid robot production, aiming for 1 million units annually by 2030 [5] - Tesla's stock saw a rise, and related companies like Siasun Robot & Automation also experienced gains [5] Gold Mining Sector - Zijin Mining's subsidiary, Zijin Gold International, is set to list on the Hong Kong Stock Exchange, marking a significant IPO in the gold mining sector [6] - The company is projected to see a compound annual growth rate of 21.4% in production and 61.9% in net profit from 2022 to 2024 [6] New Listings Performance - New listings like Botai Carlink and Xipuni performed well, with significant price increases post-IPO [7] Apple iPhone Demand - Morgan Stanley reported strong demand for the iPhone 17 series, with delivery times remaining high compared to last year [8] - The iPhone 17 series is expected to support Apple's Q4 performance despite weaker demand for the Air model [8] Bilibili's Financial Performance - Bilibili reported Q2 revenue of 7.34 billion yuan, a 20% year-on-year increase, with a net profit of 220 million yuan [10] - The platform's user base continues to grow, with a DAU of 107 million and a MAU of 368 million [11] - Bilibili's gaming segment is performing well, with a 68% increase in mobile game revenue [11][12]

Market Overview - The Hong Kong stock market experienced fluctuations, with the Hang Seng Index closing at 23,831 points, down 145 points or 0.61% [1] - The Hang Seng Index showed a positive trend on Monday, closing up 1.89% at 26,622.88 points, with significant gains in technology stocks [1][5] - The US stock market also saw gains, with the Dow Jones up 68.78 points or 0.15%, and the Nasdaq rising 107.09 points or 0.48% [2] Capital Flows - Southbound capital in the Hong Kong Stock Connect recorded a net inflow of HKD 173 billion in September, marking a recent high [3] - Year-to-date, the cumulative net inflow has reached HKD 1,152 billion, significantly surpassing last year's total of HKD 807.9 billion [3] Sector Performance - The technology sector, particularly AI and semiconductor stocks, has shown strong performance, with companies like SMIC and Huahong Semiconductor reaching historical highs [3] - Gold stocks have performed well, with international gold prices recently surpassing USD 3,800 per ounce, driven by increased demand amid geopolitical uncertainties [9] Investment Recommendations - The report suggests focusing on sectors such as artificial intelligence, semiconductors, and industrial software, which are expected to benefit from ongoing technological advancements [3] - It also highlights the upstream non-ferrous metals sector, which is anticipated to perform well due to expectations of interest rate cuts by the Federal Reserve [3] - Companies with low valuations and high dividends in state-owned enterprises are recommended for investment [3] Company Highlights - China Mobile and China Unicom have received licenses for satellite mobile communication, indicating growth potential in the satellite communication industry [9] - The report mentions specific companies such as ZTE Corporation and China Mobile as key players to watch in the satellite communication sector [9]

Core Viewpoint - The article discusses the active participation of pharmaceutical companies, particularly Pianzaihuang, in the primary market as limited partners (LPs) in various investment funds, highlighting their strategies to seek new growth opportunities amid fluctuating performance [4][10][12]. Group 1: Pianzaihuang's Investment Activities - Pianzaihuang has committed to invest RMB 200 million as a limited partner in the CICC (Zhangzhou) Medical Industry Investment Partnership, representing 20% of the fund's target size of RMB 1 billion [4][6]. - This marks Pianzaihuang's third investment as an LP since 2025, following previous investments in the "Zhaoying Huikang Fund" and the "Gaoxin Runxin Fund," both with a scale of RMB 1 billion [4][11]. - The company has a strong cash reserve of nearly RMB 5 billion as of June 2025, allowing it to actively engage in investment activities despite recent declines in revenue and profit [12]. Group 2: Fund Details and Partners - The CICC Medical Fund aims to invest in sectors such as traditional Chinese medicine, biomedicine, medical devices, and health services, with a focus on projects related to Pianzaihuang's industry chain [6][8]. - The fund has seven limited partners, with several having connections to Pianzaihuang, indicating a strategic alignment within the investment ecosystem [8]. Group 3: Broader Industry Trends - Other pharmaceutical companies, such as Taige Pharmaceutical and Jiuzhoutong, are also becoming active LPs in the primary market, reflecting a trend among biopharmaceutical firms to diversify their investment portfolios [4][13]. - Companies like Hengrui Medicine and Kanglong Huacheng are also establishing significant investment funds, indicating a robust interest in the primary market driven by strong financial performance [14][16]. - The trend of pharmaceutical companies acting as LPs is seen as a positive signal for the venture capital and private equity landscape, providing much-needed capital to startups and investment firms [17].

Core Insights - The article highlights significant changes in the stock holdings of various companies under the Hong Kong Stock Connect program, indicating shifts in investor sentiment and potential investment opportunities. Group 1: Stock Increases - Canggang Railway (02169) saw the largest increase in stock holdings, rising by 10.72% to a total holding of 33.06% [1][2] - Goldwind Technology (02208) experienced a 1.17% increase, bringing its holding to 48.64% [1][2] - Zhongchu Innovation (03931) had a 1.02% increase, resulting in a holding of 14.69% [1][2] - The top three companies with the highest increases over the last five trading days were Dazhong Public Utilities (01635) with a 26.45% increase, Canggang Railway (02169) with a 21.07% increase, and Shankao Holdings (00412) with a 12.67% increase [1][3] Group 2: Stock Decreases - Shandong Molong (00568) recorded the largest decrease in stock holdings, dropping by 1.69% to 55.70% [1][2] - Jinli Permanent Magnet (06680) saw a decrease of 1.65%, resulting in a holding of 22.36% [1][2] - Yihua Tong (02402) experienced a 0.89% decrease, bringing its holding to 19.98% [1][2] - Over the last five trading days, the largest decreases were noted for Dongfang Electric (01072) with a 5.93% decrease, Yihua Tong (02402) with a 4.16% decrease, and Ocean Park (02255) with a 2.54% decrease [1][3] Group 3: Long-term Trends - Over the past 20 days, Dazhong Public Utilities (01635) had the highest increase of 27.37%, reaching a holding of 60.02% [4] - Canggang Railway (02169) also saw a significant increase of 21.39%, maintaining a holding of 33.06% [4] - Longfei Optical Fiber and Cable (06869) increased by 17.15%, achieving a holding of 71.17% [4]

Group 1: Robotics and Semiconductor - The company in the robotics sector has not established partnerships with Yushu, Ubtech, or Tesla in the embodied intelligence business [1] - Jiejia Weichuang is continuously receiving new orders for its semiconductor cleaning equipment [1] Group 2: Chemical and Media - Nanjing Julong's products do not involve ultra-high molecular weight polyethylene materials [2] - Guangxian Media is actively exploring the micro-short drama field and is planning to invest in establishing related companies [2] - Huashu Media is engaged in long-term business cooperation with Alibaba's enterprises in various aspects of internet television [2] Group 3: Electronics and Other Industries - The demand for panel inventory has gradually recovered since the third quarter, leading to a recovery in industry operating rates for BOE A [2] - The company Aili Home's overseas sales from its two major bases in North America are expected to exceed 50% of its revenue for the first time in September [2] - Tianlong Group's subsidiary provides internet marketing services for major clients like JD.com on the Whale Hong Energy platform [2]